Meiji Yasuda Asset Management Co Ltd. Has $327,000 Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Meiji Yasuda Asset Management Co Ltd. lifted its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 11.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,112 shares of the biotechnology company’s stock after acquiring an additional 112 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Axon Enterprise were worth $327,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ICA Group Wealth Management LLC bought a new position in shares of Axon Enterprise in the fourth quarter valued at approximately $26,000. Blue Trust Inc. raised its holdings in Axon Enterprise by 987.5% in the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 79 shares during the period. Trivant Custom Portfolio Group LLC acquired a new position in Axon Enterprise during the 1st quarter worth $31,000. First PREMIER Bank bought a new stake in Axon Enterprise during the first quarter valued at about $33,000. Finally, Rise Advisors LLC grew its position in shares of Axon Enterprise by 49.0% in the first quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 47 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Axon Enterprise

In other news, Director Matthew R. Mcbrady sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $364.66, for a total transaction of $729,320.00. Following the completion of the sale, the director now owns 4,892 shares of the company’s stock, valued at $1,783,916.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total value of $167,863.50. Following the transaction, the director now owns 7,379 shares of the company’s stock, valued at $2,752,588.37. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Matthew R. Mcbrady sold 2,000 shares of the firm’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the sale, the director now owns 4,892 shares of the company’s stock, valued at $1,783,916.72. The disclosure for this sale can be found here. Insiders sold 317,981 shares of company stock valued at $115,662,734 in the last ninety days. Insiders own 6.10% of the company’s stock.

Axon Enterprise Trading Up 0.9 %

AXON stock opened at $393.29 on Friday. Axon Enterprise, Inc. has a 1-year low of $189.12 and a 1-year high of $393.58. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The business’s 50 day moving average is $348.04 and its 200-day moving average is $317.22. The firm has a market cap of $29.72 billion, a P/E ratio of 115.00, a P/E/G ratio of 10.34 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm had revenue of $504.00 million during the quarter, compared to analyst estimates of $478.35 million. During the same period in the prior year, the company posted $0.80 earnings per share. The business’s revenue for the quarter was up 34.5% compared to the same quarter last year. Equities analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AXON. Barclays boosted their price objective on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. JMP Securities increased their price objective on Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Jefferies Financial Group initiated coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a report on Wednesday, August 7th. Finally, Robert W. Baird raised their price target on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.